Total current liabilities 6,812,932 7,273,296
Warrant liability 7,860,000 2,100,000
Deferred contract revenue 11,625,000 11,625,000
Deferred rent and credit on lease
concession 990,746 1,177,840
Total liabilities 27,288,678 22,176,136
Noncontrolling interest 7,157,781 7,337,811
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, undesignated - -
Common stock, par value 560,763 467,488
Capital in excess of par value 210,523,235 189,019,188
Accumulated deficit (212,841,581) (195,334,828)
Accumulated other comprehensive
income 373 -
Total stockholders' equity
(deficit) (1,757,210) (5,848,152)
Total liabilities,
noncontrolling interest and
stockholders' equity (deficit) $32,689,249 $23,665,795
MIDDLEBROOK PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended June 30,
2008 2007
Cash flows from operating activities:
Net loss $(17,506,753) $(23,140,917)
Adjustments to reconcile net income
to net cash in operating
activities:
Loss attributable to
noncontrolling interest (180,030) -
Depreciation and amortization
'/>"/>
| SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |